Organization
Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea
14 abstracts
5 posters
Abstract
ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer.Org: Shizuoka Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Beijing Cancer Hospital, Department of Oncology, National Taiwan University Hospital,
Abstract
Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).Org: Memorial Sloan Kettering Cancer Center, Kyushu University, University Hospital Essen, P.A. Herzen Moscow Oncological Research Institute, University of Miami Sylvester Comprehensive Cancer Center,
Abstract
Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC.Org: Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Memorial Sloan Kettering Cancer Center, Vall d’Hebron University Hospital/VHIO, Lausanne University Hospital, William Osler Health System,
Abstract
ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).Org: Sarah Cannon Research Institute/Tennessee Oncology, Jilin Cancer Hospital, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Federal State Budgetary Institution “N. N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Beijing Cancer Hospital,
Abstract
Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL.Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul National University Hospital, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Department of Hematology-Oncology,
Abstract
Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.Org: Memorial Sloan Kettering Cancer Center, University of Bari "A. Moro" and Policlinico Consorziale, Kyushu University, Texas Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea,
Abstract
Myosteatosis on computed tomography as a predictor of therapeutic response to CDK4/6 inhibitors plus aromatase inhibitors in patients with advanced breast cancer.Org: Yonsei University College of Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Endocrine Research Institute, Severance Hospital, Division of Medical Oncology, National Cancer Center Singapore,
Abstract
Patient-reported outcomes in N1 breast cancer: A phase III trial comparing whole-breast to whole-breast plus regional irradiation after taxane-based chemotherapy (KROG 1701).Org: Samsung Medical Center, Chonnam National University Medical School and CNU Hwasun Hospital, Asan Medical Center, Soonchunhyang University Hospital, Gil Medical Center,
Abstract
Genomic landscape and therapeutic implications in advanced solid cancers: KOSMOS-II (KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors, KCSG AL-22-09).Org: Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, National Cancer Center Hospital East, Kashiwa, Japan, Goyang-Si, South Korea, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy,
Abstract
Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).Org: University of Milan and European Institute of Oncology, IRCCS, Fudan University Shanghai Cancer Center, Division of Medical Oncology, National Cancer Centre of Singapore, National Cancer Center Hospital East, Kashiwa, Japan, Latin American Cooperative Oncology Group (LACOG),
Abstract
Nationwide real-world practice pattern and clinical data of palbociclib in patients with HR(+), HER2(-) metastatic breast cancer (KCSG BR21-15).Org: Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, Department of Internal Medicine, Seoul National University Hospital, Seoul, Seoul, South Korea, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
Immune phenotype profiling based on anatomic origin of melanoma and impact on clinical outcomes of immune checkpoint inhibitor treatment.Org: Lunit Inc., Yonsei University College of Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Stanford University School of Medicine,
Abstract
A phase II study of nivolumab in patients with recurrent or metastatic carcinosarcomas.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Seoul National University Hospital, Division of Hematology-Oncology, Department of Medicine, Seoul Medical Center, Seo-Gu, South Korea, Department of Medicine, Icahn School of Medicine at Mount Sinai, Samsung Medical Center,
Abstract
Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with PD-L1 ≥ 50%: Cohort A of EVOKE-02.Org: Northwestern University Feinberg School of Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Regional and Virgen de la Victoria University Hospitals, IBIMA, Hospital Clínic de Barcelona, IDIBAPS,